Literature DB >> 4182531

Obtention and assay of rabbit anti-Pseudomonas serum.

H F Laborde, C Legnani de Fajardo.   

Abstract

Inoculation of rabbits with a nonliving anti-Pseudomonas vaccine induced appreciable levels of agglutinating antibodies against strains of P. aeruginosa included or not included in the vaccine. Serum obtained from vaccinated rabbits was able to confer temporary protection to mice against challenge with homologous or heterologous strains of Pseudomonas. When two or three doses of serum were used, all mice survived the challenge dose for more than 48 hr, but some of the animals died 10 days after challenge. When five doses of serum were used, all mice survived this 10-day period, and even 4 months later they did not show any sign of infection. Serum treatment temporarily inhibited Pseudomonas activity and allowed for the activation of the immunogenic mechanisms of the animals. This was corroborated by the fact that mice treated with three doses of serum and surviving the challenge dose for more than 20 days were immune against a second challenge. Anti-Pseudomonas gamma globulin conferred a lower degree of protection against homologous or heterologous strains of Pseudomonas.

Entities:  

Mesh:

Substances:

Year:  1969        PMID: 4182531      PMCID: PMC315285          DOI: 10.1128/jb.98.3.992-995.1969

Source DB:  PubMed          Journal:  J Bacteriol        ISSN: 0021-9193            Impact factor:   3.490


  8 in total

1.  Measurement of the protective effect of antibody in burned and unburned patients' sera for Pseudomonas aeruginosa infected mice.

Authors:  C D GRABER; D CUMMINGS; E H VOGEL; W T TUMBUSCH
Journal:  Tex Rep Biol Med       Date:  1961

2.  Efficacy of rabbit pseudomonas antiserum in experimental Pseudomonas aeruginosa infection.

Authors:  R C MILLICAN; J D RUST
Journal:  J Infect Dis       Date:  1960 Nov-Dec       Impact factor: 5.226

3.  Role of infection in mortality from severe burns. Evaluation of plasma, gamma-globulin, albumin and saline-solution therapy in a group of Peruvian children.

Authors:  N A KEFALIDES; J A ARANA; A BAZAN; M BOCANEGRA; P STASTNY; N VELARDE; S M ROSENTHAL
Journal:  N Engl J Med       Date:  1962-08-16       Impact factor: 91.245

4.  Immunity to Pseudomonas pyocyanea in man.

Authors:  J E FOX; E J LOWBURY
Journal:  J Pathol Bacteriol       Date:  1953-04

5.  Immunity and antibody to Pseudomonas pyocyanea in rabbits.

Authors:  J E FOX; E J LOWBURY
Journal:  J Pathol Bacteriol       Date:  1953-04

6.  Pseudomonas Vaccine I. Preparation and Assay.

Authors:  H F Laborde; C L de Fajardo
Journal:  J Bacteriol       Date:  1965-07       Impact factor: 3.490

7.  Fatal pseudomonas infection in burned patients. A clinical, bacteriologic and anatomic study.

Authors:  E R RABIN; C D GRABER; E H VOGEL; R A FINKELSTEIN; W A TUMBUSCH
Journal:  N Engl J Med       Date:  1961-12-21       Impact factor: 91.245

8.  Pseudomonas vaccine. 3. Evaluation of a polyvalent vaccine.

Authors:  C L De Fajardo; H F Laborde
Journal:  J Bacteriol       Date:  1968-05       Impact factor: 3.490

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.